Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 65,000 Class A shares of the company on 03/28/2024, with an aggregate market value of $656,500. The shares to be sold were acquired through various transactions dating back to September 1, 2016, including founders shares, stock option exercises, and restricted stock vesting. The most recent acquisition was on May 15, 2023, when Gibson received 1,507 shares as compensation. This planned sale follows a series of transactions over the past three months, where a total of 165,444 shares were sold for gross proceeds of approximately $1.69 million. The notice for the upcoming sale was filed on the same date as the planned sale, with the sale plan having been adopted on December 27, 2023.

Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 65,000 Class A shares of the company on 03/28/2024, with an aggregate market value of $656,500. The shares to be sold were acquired through various transactions dating back to September 1, 2016, including founders shares, stock option exercises, and restricted stock vesting. The most recent acquisition was on May 15, 2023, when Gibson received 1,507 shares as compensation. This planned sale follows a series of transactions over the past three months, where a total of 165,444 shares were sold for gross proceeds of approximately $1.69 million. The notice for the upcoming sale was filed on the same date as the planned sale, with the sale plan having been adopted on December 27, 2023.